Early markers for protective mechanisms during rush venom immunotherapy

Area of Science:

• Immunology
• Allergy Research

Background:

• Allergen-specific venom immunotherapy (VIT) is the primary treatment for hymenoptera venom allergies.
• Early induction of protective and tolerogenic pathways during VIT is not well understood.

Purpose of the Study:

• To identify the earliest peripheral blood markers of protective mechanisms during the build-up phase of VIT.

Main Methods:

• Peripheral blood mononuclear cells (PBMCs) and monocytes were isolated from 65 patients.
• Tolerogenic marker expression (mRNA/protein) and serum factors were analyzed during a 5-day build-up phase.

Main Results:

• Within hours of the first injection, increased tryptophan degradation, monocyte ILT4 expression, and T cell IL-10 production were observed.
• By day 3, increased IL-10 serum levels, monocyte apoptosis, and intracellular cAMP were noted.
• Day 5 showed higher monocyte ILT3 expression and IL-10 secretion.

Conclusions:

• Tryptophan depletion, ILT3/4-mediated inhibition, IL-10 production, and intracellular cAMP contribute to early protective mechanisms in VIT.
• These findings offer insights into the rapid onset of tolerance during VIT build-up.